Ptc Therapeutics (PTCT) |
|
47.39 0.37 (0.79%)
|
08-07 14:38 |
|
Open: |
47.16 |
Pre. Close: |
47.02 |
|
High:
|
50.38 |
Low:
|
46.975 |
|
Volume:
|
823,534 |
Market Cap:
|
3,208M |
|
|
|
|
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
47.427 - 47.669 |
47.669 - 47.855 |
|
Low:
|
44.235 - 44.481 |
44.481 - 44.669 |
|
Close:
|
46.616 - 47.044 |
47.044 - 47.373 |
|
Technical analysis |
as of: 2020-08-07 2:29:39 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 61.94 One year: 67.90 |
| Support: |
Support1: 44.78 Support2: 37.26 |
| Resistance: |
Resistance1: 53.03 Resistance2: 58.13 |
| Pivot: |
48.24  |
| Moving Average: |
MA(5): 48.50 MA(20): 49.87
MA(100): 48.87 MA(250): 47.02 |
| MACD: |
MACD(12,26): -1.03 Signal(9): -1.05 |
| Stochastic oscillator: |
%K(14,3): 29.61 %D(3): 25.38 |
| RSI: |
RSI(14): 51.49 |
| 52-week: |
High: 59.89 Low: 30.79 Change(%): 8.7 |
| Average Vol(K): |
3-Month: 77440 10-Days: 121903 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.PTCT has closed below upper band by 18.1%. Bollinger Bands are 36.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Fri, 07 Aug 2020
FDA OKs PTC Therapeutics' spinal muscular atrophy treatment Evrysdi - Seeking Alpha
Fri, 07 Aug 2020
PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam) for the Treatment of Spinal Muscular Atrophy in Adults and Children 2 months and older - PRNewswire
Thu, 06 Aug 2020
Credit Suisse Sticks to Its Hold Rating for PTC Therapeutics (PTCT) - Smarter Analyst
Thu, 06 Aug 2020
PTC Therapeutics' Mary Frances Harmon Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine - PRNewswire
Wed, 05 Aug 2020
PTC Therapeutics (PTCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Wed, 05 Aug 2020
PTC Therapeutics (PTCT) Misses Q2 EPS by 148c - StreetInsider.com
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: Nasdaq Global Select |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
66 |
| Shares Float (M) |
57 |
|
% Held by Insiders
|
3.21 |
|
% Held by Institutions
|
99.32 |
|
Shares Short (K)
|
5,250 |
|
Shares Short P. Month (K)
|
4,400 |
Stock Financials |
|
EPS
|
-4.830 |
|
EPS Est This Year
|
-2.350 |
|
EPS Est Next Year
|
-1.970 |
|
Book Value (p.s.)
|
8.430 |
|
Profit Margin
|
-90.83 |
|
Operating Margin
|
-73.65 |
|
Return on Assets (ttm)
|
-10.5 |
|
Return on Equity (ttm)
|
-56.1 |
|
Qtrly Rev. Growth
|
27.4 |
|
Gross Profit (p.s.)
|
0.570 |
|
Sales Per Share
|
4.903 |
|
EBITDA (p.s.)
|
-3.088 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-138 |
|
Levered Free Cash Flow (M)
|
-90 |
Stock Valuations |
|
PE Ratio
|
-10.42 |
|
PEG Ratio
|
|
|
Price to Book value
|
5.97 |
|
Price to Sales
|
10.27 |
|
Price to Cash Flow
|
-23.97 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
